Good morning,
Welcome to new readers, and thank you to those who join us each week.
In today's edition:
- Vienna backs Neu Marx life sciences centre with €170 million
- Barcelona AstraZeneca R&D hub acquired for €385 million
- Whitechapel launches applied healthcare innovation district
- 🔒 Saarlouis pharma production site secures €480 million
- 🔒 Valencia opens no-alcohol beverage processing facility
- 🔒 Ulm science park secures long-lease lab tenant
- 🔒 Oss Pivot Park reactivates lab building
- 🔒 Liverpool innovation hub attracts international tenants
- 🔒 Manchester biotech opens GLP-ready laboratories
- 🔒 Marseille pharma-led urban logistics asset acquired
- 🔒 Merseyside pharma group leases distribution facility
(🔒 = for paying members only. Subscribe here to unlock).
Enjoy today's newsletter,
— Stephen Ryan (connect with me on LinkedIn)
1. Vienna backs Neu Marx life sciences centre with €170 million
The City of Vienna has approved €170 million in funding for the Life Science Center Vienna in the Neu Marx district near the Vienna BioCenter.
The Vienna Business Agency will develop approximately 14,000 sq m of laboratory and office space with technical infrastructure, including computing and server capacities in the basement.
AITHYRA, the Institute for Artificial Intelligence in Biomedicine, will occupy around half the space as anchor tenant from 2029, funded by the Boehringer Ingelheim Foundation with €150 million over 12 years.
Planning is scheduled for 2026, with construction starting in 2027 and completion in 2029. The centre will accommodate approximately 500 positions.
2. Barcelona AstraZeneca R&D hub acquired for €385 million
InmoCaixa, the real estate arm of CriteriaCaixa, has acquired the Estel building from Freo and Bain Capital for around €385 million.
Built in 1972 and substantially renovated at a cost of more than €80 million, the property offers 52,000 sq m of gross leasable space and is 93 per cent occupied.
The principal tenant is AstraZeneca, which operates its European R&D hub from the building, housing 1,600 professionals and running 385 research projects and 190 clinical trials. Other tenants include Airbus and Codeway.
🔍 Need deeper insight into life sciences real estate?
In addition to this newsletter, we deliver bespoke research and strategic analysis for investors and developers — from acquisition support to market mapping and custom reporting.
Get in touch to discuss your next project.
3. Whitechapel launches applied healthcare innovation district
HIG Capital has formed a partnership with Barts Health NHS Trust to deliver a 170,000 sq ft applied healthcare innovation building at Cavell Street in Whitechapel, east London.
The development represents the first building within the newly launched Barts Life Sciences Cluster, which integrates The Royal London Hospital and is adjacent to Queen Mary University of London.
The cluster partnership includes private investors BGO and Lateral. Once operational, the 25 acre district will comprise 5 million sq ft of innovation, workspace, academic and clinical facilities.
👇 As a free member, you’re only seeing 3 of 11 deals this week.
Subscribers see them all so why not take a 14-day trial?
